On September 8, 2022 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, reported that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City (Press release, Mustang Bio, SEP 8, 2022, View Source [SID1234619273]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

H.C. Wainwright 24th Annual Global Investment Conference: The company will present a corporate update on Monday, September 12, 2022, at 9:30 a.m. ET and will participate in one-on-one meetings during the conference. A webcast of the company’s presentation will be available on the News & Events page of the Investor Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days after the meeting.
Cantor Cell & Gene Therapy Conference: The company will participate in a panel presentation on Thursday, September 15, 2022, at 10:40 a.m. ET, titled, "You Can’t Get Anywhere without the CAR-T Keys or GMP Van: Why Manufacturing is Essential." The company will also participate in one-on-one meetings during the conference.